Home LiteratureArticle Details
PMID: 1942942 Published · ppublish ger English Abstract Journal Article

[Thrombolysis with rt-PA in children with arterial and venous thromboses--a new therapy concept].

Thrombolyse mit rt-PA bei Kindern mit arteriellen und venösen Thrombosen--ein neuer Therapieansatz.

Klinische Padiatrie ·Vol. 203 ·No. 5 ·1991-00-00 ·Pages 359-62

Nowak-Göttl U, Kreuz WD, Schwabe D, Linde R, Kornhuber B

Abstract

Thrombolytic therapy usually used for thrombosis in the adult has been administered as a therapeutic regiment in pediatric patients (parental consent was sought prior to the treatment with rt-PA). We report our experience with rt-PA in 17 children and adolescents suffering from arterial (n = 4) or venous thrombosis (n = 13) due to local rhabdomyosarcoma, acute lymphoblastic leukemia, chronic myeloblastosis, sickle cell anaemia, parenteral nutrition, haemolytic uremic syndrome, central arterial and venous catheters and septicemia Thrombotic diseases have been diagnosed by Doppler ultrasound, computed tomography, angiography and phlebography. Rt-PA therapy was started immediately after diagnostic procedures had been performed. Rt-PA dose varied from 0.2 mg as a single dose to 0.8 mg/kg bw/d over a three day period in children local thrombolysis was performed. In patients requiring systemic thrombolytic therapy rt-PA was administered from 0.8 mg/kg bw/d in three days to 2.0 mg/kg bw/d over a whole period of three weeks in both groups during thrombolysis low dose heparin was added. When rt-PA infusion was terminated heparin (70 IU - 400 IU/kg bw/d) was administered for 7 to 14 days in order to prevent reocclusion. Later prophylaxis with coumarin derivatives in venous thrombosis and antiplatelet agents in arterial occlusive diseases was performed. In no patient did we see a decrease of fibrinogen and plasminogen during rt-PA therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

MeSH Terms
Adolescent Child Child, Preschool Drug Therapy, Combination Female Heparin/administration & dosage Humans Infant Infant, Newborn Infusions, Parenteral Male Postphlebitic Syndrome/prevention & control Recombinant Proteins/therapeutic use Thrombosis/drug therapy,etiology Tissue Plasminogen Activator/administration & dosage,therapeutic use
Chemicals
Recombinant Proteins Heparin Tissue Plasminogen Activator
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Nowak-Göttl U
Zentrum der Kinderheilkunde, J.W. Goethe-Universität, Frankfurt/Main.
Kreuz W D
Schwabe D
Linde R
Kornhuber B
Article Info
Journal
Klinische Padiatrie
Abbr.
Klin Padiatr
ISSN
0300-8630
Published
1991-00-00
Pages
359-62
Language
ger
Region
Germany
NLM ID
0326144
Subset
IM
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com